Showing 1 - 9 results of 9 for search 'Chris Wynne', query time: 0.04s Refine Results
  1. 1
    Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1, Randomized, Double-Blind Study

    Pharmacokinetics, Safety, Tolerability, and Immunogenicity of BP02 (Trastuzumab Biosimilar) Compared to EU- and US-Approved Trastuzumab in Healthy Adult Male Volunteers: A Phase 1,... by Christian Schwabe, Chris Wynne, Dayaker Reddy Dyapa, Arpitkumar Prajapati, Disha Dadke

    Published 2024-07-01
    Get full text
    Article
  2. 2
    476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19

    476 AK119, a humanized anti-CD73 monoclonal antibody, as Immunotherapy for COVID-19 by Na Chen, Tingting Zhong, Zhaoliang Huang, Xinghua Pang, Konyew Kwek, Chris Wynne, Adam Konpa, Maxwell Zhongmin Wang

    Published 2020-11-01
    Article
  3. 3
    Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial

    Immunogenicity and safety of a proposed pegfilgrastim biosimilar MSB11455 versus the reference pegfilgrastim Neulasta® in healthy subjects: A randomized, double‐blind trial by Chris Wynne, Christian Schwabe, Emmanuelle Vincent, Armin Schueler, Janka Ryding, Martin Ullmann, Vishal Ghori, Radmila Kanceva, Michael Stahl

    Published 2020-04-01
    Get full text
    Article
  4. 4
    Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial

    Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial by Allison Steigler, James W. Denham, David S. Lamb, Nigel A. Spry, David Joseph, John Matthews, Chris Atkinson, Sandra Turner, John North, David Christie, Keen-Hun Tai, Chris Wynne

    Published 2012-01-01
    Get full text
    Article
  5. 5
    Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers

    Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers by Rui Zhu, Hubert Chen, Joshua Galanter, Gaohong She, Fang Cai, Matthew R. Durk, Yixuan Zou, Liuxi Chen, Jane R. Kenny, Shweta Vadhavkar, Simon Warren, Glyn Taylor, Olivia Hwang, Avi Eliahu, Chris Wynne, Ryan Owen

    Published 2022-05-01
    Get full text
    Article
  6. 6
    A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.

    A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab. by Martin Demarchi, Pierre Coliat, Philippe Barthelemy, Roland Schott, Meher BenAbdelghani, Michael Kim, Jocelyn Chung Shii Hii, Peggy Feyaerts, Felicia Rui Xia Ang, Marie Paule Derde, Filip Deforce, Thierry Petit, Chris Schwabe, Chris Wynne, Lisa Soyeon Park, Xavier Pivot

    Published 2021-01-01
    Get full text
    Article
  7. 7
    Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies

    Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies by Chris Wynne, Abundio Balgos, Jingxin Li, Paul Hamilton, Louie Tirador, Anjuli May Jaen, Chen Mo, Zijing Yue, Ying Ma, Qingshuang Wang, Rendu Wen, Zheng Yao, Jiaping Yu, Wenrong Yao, Jianhui Zhang, Hui Zheng, Kunxue Hong, Fengcai Zhu, Yong Liu

    Published 2023-12-01
    Get full text
    Article
  8. 8
    Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies

    Correction to: Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies by Chris Wynne, Abundio Balgos, Jingxin Li, Paul Hamilton, Louie Tirador, Anjuli May Jaen, Chen Mo, Zijing Yue, Ying Ma, Qingshuang Wang, Rendu Wen, Zheng Yao, Jiaping Yu, Wenrong Yao, Jianhui Zhang, Hui Zheng, Kunxue Hong, Fengcai Zhu, Yong Liu

    Published 2024-06-01
    Get full text
    Article
  9. 9
    First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers

    First‐in‐human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC‐2394, in healthy volunteers by Fei Tang, Rebecca Kunder, Tom Chu, Avis Hains, Allen Nguyen, Jacqueline M. McBride, Yu Zhong, Sara Santagostino, Maria Wilson, Abigail Trenchak, Liuxi Chen, Justin Ly, Anita Moein, Nicholas Lewin‐Koh, Vibha Raghavan, Uyi Osaghae, Chris Wynne, Ryan Owen, David Place

    Published 2023-09-01
    Get full text
    Article

Search Tools: